Novel IKKβ inhibitors discovery based on the co-crystal structure by using binding-conformation-based and...

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Drug Discovery

Background:

• IκB kinase β (IKKβ) is a critical regulator of the NF-κB signaling pathway.
• IKKβ is a significant therapeutic target for anti-inflammatory and anti-cancer drug development.

Purpose of the Study:

• To identify novel inhibitors of IKKβ using a hybrid structure-based and ligand-based approach.
• To leverage the co-crystal structure of IKKβ for rational drug design.

Main Methods:

• Classification of 162 known IKKβ inhibitors into five classes based on chemical similarity.
• Generation of 3D pharmacophore models for each class using binding conformations.
• Virtual screening of compounds using validated pharmacophore models.

Main Results:

• Twelve drug-like compounds were selected for biological evaluation.
• Two novel IKKβ inhibitors were identified with IC50 values below 10 μM.
• This study represents the first use of the IKKβ crystal structure in this combined modeling approach.

Conclusions:

• The integrated structure- and ligand-based strategy is effective for discovering novel IKKβ inhibitors.
• The identified compounds show promise as starting points for developing new anti-inflammatory and anti-cancer agents.
• Incorporating structural information enhances the virtual screening process for drug discovery.